Physiomics plc (LSE:PYC) has announced a series of new contract wins during May valued at more than £345,000, including both new and repeat business with UK and international biotechnology and oncology-focused organisations. Among the agreements is work for a NASDAQ-listed clinical-stage biotechnology company. The contracts draw on Physiomics’ capabilities in modelling, simulation and data science to support Phase 1 and Phase 2 clinical analysis, first-in-human dose selection and wider clinical development programmes.
The projects are expected to generate revenue through to the end of 2027 while strengthening the company’s order book, client relationships and standing within the biotechnology and pharmaceutical industries. Management said the latest contract awards further demonstrate demand for Physiomics’ specialist expertise across oncology and drug development services.
The company’s outlook continues to be weighed down by weak financial performance, including ongoing net losses and recurring negative operating and free cash flow, despite maintaining a relatively low-debt balance sheet. Technical indicators are more supportive, with the share price trading above key moving averages and showing positive MACD momentum. Valuation remains mixed due to the company’s negative price-to-earnings ratio and the absence of a dividend yield.
More about Physiomics
Physiomics plc (LSE:PYC) is a UK-based specialist in mathematical modelling, data science and biostatistics focused on supporting biotechnology and pharmaceutical companies in drug development and personalised medicine. The company uses modelling and simulation, biometrics, bioinformatics and its proprietary Virtual Tumour platform to optimise discovery, pre-clinical and clinical programmes, working with a range of major pharmaceutical and oncology-focused biotechnology clients.
Leave a Reply